鼻用氯硝柳胺对ANCA相关血管炎鼻部症状的影响
PROTECT-V平台试验的回顾性亚组分析纳入32例ANCA相关血管炎患者(14例鼻用氯硝柳胺,18例安慰剂),治疗期间氯硝柳胺组耳鼻喉症状发生率7%显著低于安慰剂组39%(P=0.04)。治疗前及治疗后9个月两组无显著差异。
要点
- 治疗期间氯硝柳胺组耳鼻喉症状发生率7%显著低于安慰剂组39%(P=0.04)。
- PR3-ANCA阳性患者中,氯硝柳胺组0/10出现耳鼻喉症状,安慰剂组5/9(56%)出现。
- 治疗前后9个月两组耳鼻喉症状无显著差异。
核心结论
- 鼻用氯硝柳胺对ANCA相关血管炎的耳鼻喉表现显示出潜在临床效应的信号。
- 结果支持IL-6和STAT3通路在ANCA相关血管炎中的作用,鼻用氯硝柳胺或该通路其他候选药物值得进一步评估。
研究设计与样本
- PROTECT-V是一项评估COVID-19暴露前预防药物的随机、双盲、安慰剂对照平台试验。
- 本亚组分析纳入单中心32例ANCA相关血管炎患者(14例鼻用氯硝柳胺,18例安慰剂),回顾性收集治疗前9个月、治疗期间及治疗后9个月的临床数据,研究者对治疗分配设盲。
主要发现
- 治疗期间耳鼻喉症状在氯硝柳胺组14例中1例(7%)出现,安慰剂组18例中7例(39%)出现(P=0.04)。
- 治疗前9个月及治疗后9个月两组耳鼻喉症状无显著差异。
- PR3-ANCA阳性患者中,治疗期间氯硝柳胺组10例中0例出现耳鼻喉症状,安慰剂组9例中5例(56%)出现。
- 患者中11例(34%)为女性,中位年龄69岁(IQR 59-75),中位既往AAV病程5.4年(IQR 1.9-13.1),19例(59%)在治疗前一年内有活动性疾病,中位治疗暴露200天(IQR 109-251)。
临床怎么用
- 对于ANCA相关血管炎患者,鼻用氯硝柳胺可能减少治疗期间的耳鼻喉症状,尤其PR3-ANCA阳性者。
- 该结果仅为信号,需进一步随机对照试验验证后方可常规用于临床。
局限性
- 本研究为单中心回顾性亚组分析,样本量小(32例),结果需谨慎解读。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ear, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)-AAV. In a zebrafish model, niclosamide inhibits PR3-induced granuloma formation. We hypothesized that intranasal niclosamide would reduce AAV-associated ENT symptoms. METHODS: PROTECT-V was a randomized, double-blind, placebo-controlled platform trial evaluating pre-exposure prophylaxis agents against COVID-19 infection. This subanalysis includes patients from a single center with AAV, enrolled into the intranasal niclosamide arm. Clinical data were retrospectively collected for nine months before, during, and nine months after treatment. Researchers were blinded to treatment allocation. RESULTS: Of 32 (14 niclosamide; 18 placebo) patients, 11 (34%) were female; the median age was 69 (interquartile range [IQR] 59-75) years. Median prior AAV disease duration was 5.4 (IQR 1.9-13.1) years; 19 (59%) had active disease in the year before treatment. Median treatment exposure was 200 (IQR 109-251) days. During treatment, ENT symptoms were identified in 1 of 14 (7%) of the niclosamide group compared with 7 of 18 (39%) of the placebo group (P = 0.04). No significant difference between groups was found in the nine months before or after treatment. Among PR3-ANCA-positive patients, 0 of 10 in the niclosamide group compared to 5 of 9 (56%) in the placebo group had ENT symptoms during treatment. CONCLUSION: These data are a signal of potential clinical effect on ENT manifestations in AAV. They support a role for the IL-6 and STAT3 pathway in AAV; intranasal niclosamide or other drug candidates in this pathway warrant further evaluation.
引用
- Lim B, Qian W, Dowling F, et al. The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2026. PMID: 41656183. doi:10.1002/art.70061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。